Virginia Retirement Systems ET AL decreased its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 9.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,000 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in SAGE Therapeutics were worth $732,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in shares of SAGE Therapeutics by 40.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 109,054 shares of the biopharmaceutical company’s stock worth $10,441,000 after buying an additional 31,571 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of SAGE Therapeutics by 1.1% during the fourth quarter. Principal Financial Group Inc. now owns 23,202 shares of the biopharmaceutical company’s stock worth $2,222,000 after buying an additional 243 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of SAGE Therapeutics by 9.0% during the fourth quarter. Legal & General Group Plc now owns 23,039 shares of the biopharmaceutical company’s stock worth $2,207,000 after buying an additional 1,902 shares in the last quarter. Norges Bank acquired a new stake in shares of SAGE Therapeutics during the fourth quarter worth $33,075,000. Finally, Geode Capital Management LLC increased its position in shares of SAGE Therapeutics by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 467,917 shares of the biopharmaceutical company’s stock worth $44,821,000 after purchasing an additional 32,033 shares during the period.

In other SAGE Therapeutics news, CEO Jeffrey M. Jonas sold 84,661 shares of SAGE Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $174.83, for a total value of $14,801,282.63. Following the transaction, the chief executive officer now owns 97,851 shares in the company, valued at $17,107,290.33. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Cloonan sold 25,000 shares of SAGE Therapeutics stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $175.00, for a total value of $4,375,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 203,925 shares of company stock worth $35,648,917. Company insiders own 4.60% of the company’s stock.

Shares of NASDAQ SAGE opened at $165.58 on Wednesday. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. SAGE Therapeutics Inc has a 52 week low of $79.88 and a 52 week high of $193.56. The company has a market capitalization of $8.55 billion, a PE ratio of -20.49 and a beta of 2.53. The stock has a fifty day moving average of $175.23.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.32) by $0.04. The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.27 million. During the same quarter in the prior year, the firm earned ($0.36) EPS. The business’s revenue was down 99.0% on a year-over-year basis. Research analysts anticipate that SAGE Therapeutics Inc will post -13.32 earnings per share for the current year.

A number of research analysts recently commented on the company. Jefferies Financial Group assumed coverage on SAGE Therapeutics in a research report on Thursday, April 25th. They issued a “buy” rating and a $195.00 price target on the stock. Wedbush assumed coverage on SAGE Therapeutics in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $207.00 price target on the stock. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. LADENBURG THALM/SH SH set a $220.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, ValuEngine cut SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $200.27.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Read More: Holder of Record

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.